LITS | tickerfilter.com

Fundamental analysis

21%

Profitability 25%

Dept financing 3%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

4.42%

1 Month

1.72%

3 Months

-8.53%

6 Months

-43.54%

1 Year

-40.70%

2 Year

-61.31%

Key data

Stock price

$1.18

P/E Ratio

0.00

DAY RANGE

$1.14 - $1.20

EPS

$0.00

52 WEEK RANGE

$0.95 - $9.00

52 WEEK CHANGE

-$40.70

MARKET CAP

16.457 M

YIELD

N/A

SHARES OUTSTANDING

35.655 M

DIVIDEND

$1.75

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

-0.21

PUBLIC FLOAT

AVERAGE 10 VOLUME

$273,306

AVERAGE 30 VOLUME

$250,504

Company detail

CEO: Daniel P. Gold
Region: US
Website: meipharma.com
Employees: 100
IPO year: 2003

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

MEI Pharma, Inc. focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trials for patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex in Phase I clinical trial for human epidermal growth factor receptor 2 negative breast cancer.

LITS - MEI Pharma, Inc.